Curaleaf Holdings (TSX:CURA) Stock Recovers As Profitability Meets Slower Growth

Curaleaf Holdings stock has drifted over the past three months, down about 18.9%, yet yesterday it closed at CA$12.95 with investors reacting to an earnings print that finally put black ink on the income statement. The market saw an early proof point for the long medical cannabis reset as Curaleaf posted Q2 revenue of US$340.1m and net income of US$12.5m from continuing operations.

The headline is simple. Curaleaf just moved from a long stretch of losses into a profitable quarter while keeping double digit organic revenue growth in a still challenged cannabis sector.

Is Curaleaf Holdings trading at a genuine discount, or is the low P/S simply masking ongoing losses and volatile earnings? See how the current share price lines up with our valuation analysis for Curaleaf Holdings

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$340.1m vs. US$310.6m (up about 9.5%)
• Net Income from Continuing Operations, Q2 2026 vs. Q2 2025: US$12.5m vs. a loss of US$59.5m (moved into profit)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.05 vs. a loss of US$0.24 per share (returned to positive earnings per share)
• Gross Margin, Q2 2026 vs. Q2 2025: 50% vs. prior year not disclosed (indicates solid profitability on each dollar of sales)

Tired of scrolling through earnings tables and dense financial reports for Curaleaf Holdings? Get the full visual picture of the stock's valuation in a clean dashboard with our company report for Curaleaf Holdings.

Curaleaf’s Bull Case Hangs On Margin And International Proof

The upbeat story around Curaleaf Holdings is that a higher margin, pharma style cannabis platform, anchored by international growth and premium products, can scale without relying on heavy brick and mortar spending. Q2 gives some concrete proof points. Revenue grew organically about 10% with a 50% gross margin and US$70m adjusted EBITDA, and the company moved to US$12.5m of net income from continuing operations. That supports the idea that operational leverage and cost control are starting to matter more than raw volume.

The bullish focus on international expansion also shows early traction. International revenue grew 26% with progress in the U.K., Germany and Poland, while the Four 20 Pharma buyout and the Spain registration help validate the first mover ambition in medical markets. The push toward 50% to 75% vertical supply within 6 to 12 months is a clear and testable milestone for the margin uplift investors are watching.

Compare Curaleaf Holdings’ new profitability, 50% gross margin and international push with how the street is calibrating its return profile. See the consensus price target analysis for Curaleaf Holdings.

Curaleaf Bear Case: Margins Progress, Growth Fears Linger

The bearish view on Curaleaf Holdings is that price compression, high compliance costs and heavy international spend will keep margins fragile and cash flow under strain. Q2 margins and cash generation push back on the cash flow concern. A 50% gross margin, US$70m adjusted EBITDA and US$13m free cash flow show the model can generate cash even while investing about US$16m of capex in the quarter.

However, several bear milestones are still unresolved. Revenue guidance for Q3 points to only low single digit sequential growth around US$347m. That keeps alive the concern that macro pressure and regulatory uncertainty are limiting near term growth. International operations remain exposed to third party supply volatility and price pressure at the low end in Germany, which supports fears of commoditization. The need to move to 50% to 75% vertical supply within 6 to 12 months underlines that the international margin story is not yet secured.

After a quarter that finally turned profitable, are Curaleaf Holdings’ margin gains masking deeper structural pressures on earnings quality and insider behavior? Review the risk analysis for Curaleaf Holdings which shows 3 important warning signs

Own Your Next Investing Move

If Curaleaf Holdings' first profitable quarter and 50% gross margin have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a better entry point. Once you hold the stock, use the Portfolio Command Center to cut through market noise and focus on essential developments that could affect your thesis. For a longer term view, tap into collective insights through the Community and see how other investors are thinking about Curaleaf Holdings. By identifying potential catalysts and risks early, you may be able to stay more informed about the market.

Seeking Alternatives Beyond Curaleaf Holdings?

Fresh ideas can move fast. Momentum builds, prices shift and the best setups often get caught flying just before the crowd notices. Scan these under the radar lists and act now.

• Spot resilient compounding potential before momentum headlines hit by scanning a curated mix of cash rich businesses through the list of solid balance sheet and fundamentals stocks (11 results).
• Ride early breakout trends in income focused opportunities while yields still look attractive by reviewing a hand picked set of high payout candidates using the 7 dividend fortresses.
• Catch fast moving themes in smaller companies that could reset expectations by checking a focused basket of forward leaning opportunities in the 68 profitable AI stocks that aren't just burning cash.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com